PRME$4.445.93%-0.28
Pre-market: 4.37-0.07 -1.58%
Prime Medicine Inc (PRME)
Date: 2026-11-02 16:00O: 4.86H: 4.86L: 4.36C: 4.44Vol: 4.125M
Prime Medicine Inc stock is traded at $4.44, with a volume of 4,124,767. It is down -5.93% in the last 24 hours and up +48.99% over the past month. Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Previous Close:
$4.72
Open:
$4.86
24h Volume:
4,124,767
Relative Volume:
0.66
Market Cap:
$805.31M
Revenue:
$4.03M
Net Income/Loss:
-$198.37M
P/E Ratio:
-
EPS:
-$1.26
Net Cash Flow:
-$158.74M
1W Performance:
+2.07%
1M Performance:
+48.99%
6M Performance:
+30.21%
1Y Performance:
-2.63%
1-Day Range:
$0.00$0.00
1-Week Range:
$4.11$5.91
52-Week Range:
$2.67$5.91
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine IncSector
HealthcareIndustry
BiotechnologyPhone
617-465-0013Address
60 FIRST ST., CAMBRIDGE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
